{"disease":{"id":"relapsed-refractory-follicular-lymphoma","name":"relapsed refractory follicular lymphoma"},"drugs":{"marketed":[{"drug_id":"tazemetostat","indication_name":"Relapsed or Refractory Follicular Lymphoma with EZH2 Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"tazemetostat","indication_name":"Relapsed or Refractory Follicular Lymphoma without Satisfactory Alternatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"chembl-chembl1201576","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory follicular lymphoma after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"mosunetuzumab-axgb","indication_name":"Relapsed or refractory follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"LUNSUMIO","generic_name":"MOSUNETUZUMAB-AXGB","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory advanced follicular lymphoma (FL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"mosunetuzumab","indication_name":"Relapsed or refractory follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lunsumio","generic_name":"MOSUNETUZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Lunsumio works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."}],"pipeline":[],"offLabel":[],"totalMarketed":16,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04224493","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":612,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT04587388","title":"Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"European Hematology Association - Lymphoma Group","has_results":false},{"nct_id":"NCT04712097","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":478,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06149286","title":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05848765","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT05338879","title":"Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03332017","title":"A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT02600897","title":"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT04305444","title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":55,"lead_sponsor_name":"Zhejiang DTRM Biopharma","has_results":false},{"nct_id":"NCT03939026","title":"Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Allogene Therapeutics","has_results":false},{"nct_id":"NCT05467943","title":"Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT07502118","title":"NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Health Institutes of Turkey","has_results":false},{"nct_id":"NCT07418190","title":"Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06550141","title":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":false},{"nct_id":"NCT07278921","title":"Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Andrés José Maria Ferreri","has_results":false},{"nct_id":"NCT06026319","title":"CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":false},{"nct_id":"NCT07031700","title":"A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04450069","title":"CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT04488354","title":"Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT06004167","title":"Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05720052","title":"A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"MingSight Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04699461","title":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":true},{"nct_id":"NCT04844086","title":"RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Eden BioCell Ltd.","has_results":false},{"nct_id":"NCT06313996","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","has_results":false},{"nct_id":"NCT05619367","title":"A Compassionate Use (CU) Program of Odronextamab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03153462","title":"Axicabtagene Ciloleucel Expanded Access Study","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}